Prevention: Vaccines & Emergency Protection

Preventing invasive meningococcal disease (IMD) involves two main strategies: routine vaccination to build long-term immunity and emergency antibiotics for those who have been recently exposed to the bacteria. Because the disease moves so quickly, both strategies are vital for community safety ^[1].

Understanding the Two Types of Vaccines

One of the most important things to know is that one vaccine does not cover all strains of the bacteria. You need two different types of vaccines to be fully protected against the most common serogroups (A, B, C, W, and Y) ^[2].

1. MenACWY (Quadrivalent Conjugate Vaccine):
   • Who gets it: This is a routine vaccine for all pre-teens and teens. The Advisory Committee on Immunization Practices (ACIP) recommends a primary dose at 11 or 12 years, with a critical booster dose at 16 years ^[3].
   • Travel and Other Risks: It is also recommended for adults traveling to high-risk areas, such as the “meningitis belt” in Sub-Saharan Africa or for those participating in the Hajj pilgrimage.
2. MenB (Serogroup B Vaccine):
   • Routine for High-Risk: This vaccine is routinely recommended for anyone over age 10 who has specific high-risk conditions (such as complement inhibitor therapy, asplenia) or during localized outbreaks ^[4].
   • Shared Decision-Making: For healthy young adults aged 16 through 23, it is administered based on “shared clinical decision-making”—meaning you and your doctor decide if it’s right for you. Unfortunately, uptake remains suboptimal among adolescents and young adults ^[5].

(Note: Recent clinical guidance is exploring harmonized schedules and pentavalent ABCWY vaccines to simplify implementation and reduce the number of injections ^[6].)

Post-Exposure Prophylaxis (PEP)

If someone is diagnosed with IMD, the people who were in close contact with them may need immediate antibiotics to prevent them from getting sick or spreading the bacteria to others. This is called chemoprophylaxis or PEP ^[7].

Who is a “Close Contact”?

Transmission usually occurs through direct contact with oral secretions from a confirmed or suspected case ^[8]. High-risk “close contacts” typically include:

• Household members and roommates.
• Intimate partners (e.g., through kissing).
• Daycare or childcare contacts.
• Healthcare workers with direct exposure to the patient’s respiratory secretions (e.g., during high-risk procedures without proper precautions) ^[8].

Emergency Antibiotics

The goal of PEP is to eradicate nasopharyngeal carriage of the bacteria before it can cause disease.

• Urgency: Antibiotics should be started as soon as possible. Management is typically guided by local or public health authorities ^[7]. PEP is most effective when given immediately and is generally not recommended if more than 14 days have passed since the last exposure to the infected person.
• Common Medications: Doctors typically prescribe ciprofloxacin as a first-line drug, though rifampin and ceftriaxone are also utilized ^[9].
• Resistance Awareness: Clinicians should be aware of rising rates of resistance or decreased susceptibility to ciprofloxacin and rifampin in certain regions and specific clonal complexes ^[10][11].